Establishment and application of cardiovascular disease evaluation platform for HIV-infected patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027483

Enrollment

Unknown

Registered

2019-11-15

Start date

2019-12-16

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection with cardiovascular disease

Interventions

HIV-infected patients:N/A

Control group:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria for HIV infected persons: 18-65 years old; HIV serum antibody was positive; Signing the informed consent voluntarily; Inclusion criteria of control group: 18-65 years old; HIV serum antibody was negative; Signing the informed consent voluntarily;

Exclusion criteria

Exclusion criteria: Epidemiological survey of cardiovascular diseases: Combined with consciousness disorder, unable to complete the questionnaire survey. Imaging study of cardiovascular disease: Severe renal insufficiency; Currently suffering from hyperthyroidism; Have a history of allergy to iodized contrast media; Currently suffering from myasthenia gravis; Pregnancy; Serious cardiopulmonary diseases: pulmonary hypertension, bronchial asthma, heart failure, licorice fever and urticaria, etc; General condition is very bad, such as late stage of malignant tumor, systemic failure; With pacemaker; There are metals in the body, such as prosthesis, shrapnel, hemostasis clip, artificial heart valve, fixed steel plate, screw, artificial femoral head, etc; Biomarker research: Serious or unstable diseases of liver, kidney and hematopoietic system, including active hepatitis, HBV, HCV, etc; During the course of HIV infection, opportunistic infection (according to the National AIDS diagnosis and treatment guidelines) or AIDS related malignant tumors appear; Combined with active autoimmune diseases, fever of unknown cause, etc.; There are serious liver function damage, abnormal blood lipid and blood glucose and other metabolic diseases.

Design outcomes

Primary

Measure	Time frame
Carotid ultrasound;Coronary CT;Coronary MRI;biomaker detection;	—

Countries

China

Contacts

Public ContactHong Shang

The First Affiliated Hospital of China Medical University

hongshang100@hotmail.com+86 13889875242

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026